Business
DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year
DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of a new peer-reviewed study in the Journal of Medical Internet Research (JMIR), a highly influential digital health journal, evaluating healthcare utilization and medical costs among Dario users compared to matched non-users receiving usual care. The study, "Effects of a Digital Health Intervention for Adults with Type 2 Diabetes Mellitus on Health Care
About this update from Sanofi Sa
[{"type":"text","content":"Sanofi and Symphony Health teams conducted the study demonstrating how Dario's digital, diabetes intervention platform reduces real-world healthcare burden and cost compared to usual care","length":191,"tagName":"p","attribs":{}},{"type":"text","content":"Representing a high-rigor, real world analysis, the study found Dario users, as compared to matched individuals receiving usual care, had 23% lower hospitalization rates and 26% lower all-cause charges","length":201,"tagName":"p","attribs":{}},{"type":"text","content":"More frequent engagement on the Dario platform associated with fewer inpatient and ER events","length":92,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Nov. 24, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of a new peer-reviewed study in the Journal of Medical Internet Research (JMIR), a highly influential digital health journal, evaluating healthcare utilization and medical costs among Dario users compared to matched non-users receiving usual care. The study, "Effects of a Digital Health Intervention for Adults with Type 2 Diabetes Mellitus on Health Care Resource Use and Health Care Charges in the United States: Retrospective Cohort Study," was not authored by Dario, but rather conducted by researchers at Sanofi and Symphony Health.","length":766,"tagName":"p"},{"type":"image","alt":"DarioHealth logo","displaySize":"","headline":null,"caption":"DarioHealth logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":351,"url":"https://media.zenfs.com/en/prnewswire.com/aeba40a2dbbcfe9e74c653d4eb6528da"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ARomhhCf.qvSHdwl6r9xhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYxOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/aeba40a2dbbcfe9e74c653d4eb6528da","width":400,"height":351}}},{"type":"text","content":"The direct medical cost of diabetes in the U.S. was estimated at over $300 billion in 2022, with more than 38 million Americans living with diabetes, representing an estimated $31 billion serviceable addressable market for Dario.","length":229,"tagName":"p"},{"type":"text","content":"This rigorous, third-party analysis directly addresses one of the mo...